All In Biotech

Drug Trial Radar · NCT00859872

Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia

Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol IM Injection for Treatment of Acute Psychotic Agitation in Schizophrenia

Last checked: Nov 20, 2026Latest source record: Aug 3, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 198 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

198

Actual

Start

Aug 2008

Primary completion

Mar 2009

Study completion Mar 2009

Sponsor

Lead sponsor
Central South UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Wuhan Mental Health Centre; Capital Medical University; Shanghai Mental Health Center; Guangzhou Mental Hospital; Chongqing Mental Hospital
First posted
Mar 11, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-centre, open, randomized, haloperidol-referenced, 47 days two treatment sessions, parallel-group study. After screening period, eligible subjects will be entered 5 days treatment session I to compare the efficacy between risperidone oral solution combination clonazepam oral and haloperidol IM injection on controlling psychotic agitation, then will be followed by 6 additional weeks treatment session II for exploring the effect of medicine switching from IM injection to oral.

Conditions

  • Schizophrenia

Interventions

  • risperidone oral solutionDrug

    risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral

  • haloperidolDrug

    haloperidol IM injection (5-20mg/d)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the change of PANSS-EC scoresTime frame: 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MentalHealth Institute of the 2nd Xiangya Hospital, Central South University

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.